In the collaboration with Arch, Codexis will apply its novel, cost-effective Molecular-Breeding technology to manufacture an undisclosed pharmaceutical compound.
In the collaboration with Matrix, Codexis is to develop and commercialize a novel process for the manufacture of a major undisclosed pharmaceutical product.
“The generics business now accounts for a roughly $60 billion market, having grown 115% since 1998 alone,” commented Dr Alan Shaw, president and CEO of Codexis. “We believe that it is essential for Codexis to continue to expand its presence in this area, and we are pleased to extend our program with Matrix and to add Arch to our network of manufacturing partners.”
Dr Shaw went on to say that Codexis anticipates signing at least two further deals in the generics sector. And that the company expects its relationships with generics manufacturers could account for as much as 40% of the company’s revenues by 2008.